lopinavir has been researched along with Spondylarthropathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aguado, P; Balsa, A; Bernad-Pineda, M; Bogas, P; Bonilla, G; Castilla-Plaza, A; De Miguel, E; Franco-Gómez, K; García-Lorenzo, E; Miranda-Carus, ME; Monjo, I; Novella Navarro, M; Nuño, L; Peiteado, D; Rodríguez-Araya, T; Tornero, C; Villalba, A | 1 |
| Alvaro-Gracia, JM; Blanco, R; Carmona, L; Castrejón, I; Fernández Fernández, D; Fernandez-Nebro, A; Galindo, M; Gonzalez-Gay, MA; Lledó, A; Manrique-Arija, S; Martinez-Lopez, D; Mena Vázquez, N; Mera-Varela, A; Pablos, JL; Retuerto, M | 1 |
2 other study(ies) available for lopinavir and Spondylarthropathies
| Article | Year |
|---|---|
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.
Topics: Adult; Aged; Antirheumatic Agents; Antiviral Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azithromycin; Betacoronavirus; Cohort Studies; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Immunologic Factors; Lopinavir; Lupus Erythematosus, Systemic; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; Rheumatic Diseases; Ritonavir; SARS-CoV-2; Severity of Illness Index; Spondylarthropathies | 2020 |
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Antiviral Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Betacoronavirus; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Comorbidity; Connective Tissue Diseases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Glucocorticoids; Hospitalization; Humans; Hydroxychloroquine; Immunosuppressive Agents; Logistic Models; Lopinavir; Lupus Erythematosus, Systemic; Male; Middle Aged; Obesity; Pandemics; Pneumonia, Viral; Polymyalgia Rheumatica; Prognosis; Rheumatic Diseases; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Sex Factors; Sjogren's Syndrome; Spondylarthropathies | 2020 |